PT-20(PT-20) - 药物靶点：Phosphates_在研适应症：高磷血症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

Phosphates

作用机制

Phosphates 调节剂(磷酸盐调节剂)

治疗领域

内分泌与代谢疾病

在研适应症

高磷血症

非在研适应症

慢性肾病

原研机构

The Medical Research Council

在研机构

The Medical Research Council

非在研机构

Phosphate Therapeutics Ltd.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 PT-20 相关的临床试验

NCT02151643

/ Completed临床2期

Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease

The main purpose of this study is to see whether PT20 can help people with a high level of phosphate in their blood (called Hyperphosphatemia) that are being treated with dialysis for kidney disease.

开始日期2014-05-07

申办/合作机构

Phosphate Therapeutics Ltd.

[+1]

100 项与 PT-20 相关的临床结果

登录后查看更多信息

100 项与 PT-20 相关的转化医学

登录后查看更多信息

100 项与 PT-20 相关的专利（医药）

登录后查看更多信息

4

项与 PT-20 相关的文献（医药）

2022-01-01·Fish & Shellfish Immunology2区 · 农林科学

Effect of Pandanus tectorius extract as food additive on oxidative stress, immune status, and disease resistance in Cyprinus carpio

2区 · 农林科学

Article

作者: Giri, Sib Sankar ; Park, Se Chang ; Cheng, Chi

The present study investigated the effect of Pandanus tectorius (PT) extract on Cyprinus carpio growth, antioxidant capacity, immunological and oxidative stress, immune-related gene expression, and resistance against pathogen challenge. Fish (average weight: 12.18 ± 0.32 g) were fed with diets containing various concentration (g kg^-1) of PT extract: 0 g (basal diet), 5 g [PT5], 10 g [PT10], 20 g [PT20], and 30 g [PT30] for 8 weeks. Our results revealed an increase (p < 0.05) in the final weight gain only in the PT20 (63.12 ± 1.4 g) group. Activity of liver antioxidant parameters such as catalase (CAT) (27.67 ± 1.12 U mg protein^-1), superoxide dismutase (SOD) (13.17 ± 0.428 U mg protein^-1), and glutathione peroxidase (GPx) (47.14 ± 1.47 U mg protein^-1) was highest in the PT20 group. Among the serum immunological parameters examined, lysozyme (37.45 ± 0.67 U mL^-1), alternative complement pathway (133.22 ± 1.92 U mL^-1), and phagocytic activities (25.68 ± 0.93%) were high (p < 0.05) in PT20, whereas there was no significant effect on serum immunoglobulin or total protein levels, compared to the control. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and malondialdehyde (MDA) levels were found to be lower (p < 0.05) in the PT20 and PT30 groups than those in the control. However, myeloperoxidase (MPO) levels were significantly higher (p < 0.05) in the PT20 and PT30 groups. Gene expression analysis revealed that mRNA expressions of antioxidant genes (SOD, CAT, nuclear factor erythroid 2-related factor 2) and anti-inflammatory cytokine (IL-10) genes were significantly upregulated in the PT10 - PT30 groups, except for the SOD gene in PT10. Conversely, the signalling molecule NF-κBp65 was downregulated in PT20 and PT30. Expression of Toll-like receptor 22 (TLR22) and hepcidin was significantly upregulated in PT20 and PT30, respectively. Fish in the PT20 group exhibited highest relative post-challenge survival (70.37%) against Aeromonas hydrophila challenge. The results of the present study suggest that dietary supplementation of P. tectorius extract at 20 g kg^-1 can significantly improve weight gain, serum antioxidant parameters, strengthen immunity, and increase the disease resistance of C. carpio. Therefore, P. tectorius extract could be exploited for its use as a food additive in aquaculture.

2021-07-23·Nephrology Dialysis Transplantation2区 · 医学

Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: a randomized, double-blind, placebo-controlled, dose-ranging, Phase IIb study in patients with haemodialysis-dependent chronic kidney disease

2区 · 医学

Article

作者: Powell, Jonathan J ; Sampson, Mark ; Faria, Nuno

AbstractBackgroundHyperphosphataemia is a common complication of chronic kidney disease (CKD). PT20 (ferric iron oxide adipate) is an investigational molecule engineered to offer enhanced phosphate-binding properties relative to other phosphate binders.MethodsIn this double-blind, parallel-group, placebo-controlled, dose-ranging study (ClinicalTrials.gov identifier NCT02151643), the efficacy and safety of 28 days of oral PT20 treatment were evaluated in patients with dialysis-dependent CKD. Participants were randomly assigned in an 8:8:8:13:13 ratio to receive PT20 (400, 800, 1600 or 3200 mg) or placebo three times daily.ResultsAmong 153 participants, 129 completed treatment [7 discontinued because of adverse events (AEs), 2 because of hyperphosphataemia and 15 for other reasons]. PT20 treatment for 28 days resulted in a statistically significant and dose-dependent reduction in serum phosphate concentration. There were no statistically significant effects of PT20 treatment on changes in haemoglobin or ferritin concentrations or transferrin saturation between Days 1 and 29. The incidence of treatment-emergent AEs was broadly similar across the PT20 and placebo groups (42–59% versus 44%). The most common PT20 treatment-related AEs were gastrointestinal, primarily diarrhoea (13–18%) and discoloured faeces (3–23%). No serious AEs were considered to be related to study treatment. There were no clinically significant changes in laboratory results reflecting acid/base status or increases in ferritin that could indicate the absorption of components of PT20.ConclusionsIn this first study investigating the efficacy and safety of PT20 in patients with hyperphosphataemia and dialysis-dependent CKD, PT20 significantly lowered serum phosphate concentrations and was generally well tolerated.

2021-04-01·Bioactive Materials1区 · 材料科学

Implantable PEKK/tantalum microparticles composite with improved surface performances for regulating cell behaviors, promoting bone formation and osseointegration

1区 · 材料科学

ArticleOA

作者: Wei, Jie ; Wu, Zhaoying ; Mei, Shiqi ; Hu, Xinglong ; Qian, Jun ; Xie, Dong ; Zhao, Jun ; Yang, Lili ; Wang, Fan

Polyetherketoneketone (PEKK) exhibits admirable biocompatibility and mechanical performances but bioinert while tantalum (Ta) possesses excellent osteogenesis and osseointegration but high elastic modulus and density, and processing is too difficult and expensive. In the present study, combining of the advantages of both PEKK and Ta, implantable composites of PEKK/Ta were fabricated by blending PEKK with Ta microparticles of 20 v% (PT20) and 40 v% (PT40) content. In comparison with PT20 and PEKK, the surface hydrophilicity, surface energy, roughness and proteins adsorption as well as mechanical performances of PT40 significantly increased because of the higher Ta particles content in PEKK. Furthermore, PT40 exhibited the mechanical performances (e.g., compressive strength and modulus of elasticity) close to the cortical bone of human. Compared with PT20 and PEKK, PT40 with higher Ta content remarkably enhanced the responses (including adhesion, proliferation and osteogenic differentiation) of MC3T3-E1 cells in vitro. Moreover, PT40 markedly improved bone formation as well as osseointegration in vivo. In short, incorporation of Ta microparticles into PEKK created implantable composites with improved surface performances, which played key roles in stimulating cell responses/bone formation as well as promoting osseointegration. PT40 might have great potential for bear-loading bone substitute.

100 项与 PT-20 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
高磷血症	临床2期	-	The Medical Research Council	-
慢性肾病	临床前	-	Phosphate Therapeutics Ltd.	2014-05-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02151643 (CTgov)	临床2期	高磷血症 \| 慢性肾病	153	PT20 (Group 1 - PT20 400 mg Tid)	築顧遞膚壓構觸鹹壓醖(襯窪構遞淵艱廠鑰夢襯) = 壓獵窪築襯鹽鑰齋衊糧醖夢壓蓋餘構襯餘製憲 (醖製餘簾鹹糧製醖鏇齋, 鹽選築鹽艱鏇簾艱鑰壓 ~ 蓋淵獵遞壓顧觸憲壓願) 更多	-	2018-01-16
				PT20 (Group 2 - PT20 800 mg Tid)	築顧遞膚壓構觸鹹壓醖(襯窪構遞淵艱廠鑰夢襯) = 繭鏇鏇簾齋網蓋膚襯鑰醖夢壓蓋餘構襯餘製憲 (醖製餘簾鹹糧製醖鏇齋, 鏇鬱積顧獵醖顧蓋範衊 ~ 憲艱襯願壓願遞鬱積憲) 更多
ASN2015	N/A	serum phosphate \| serum ferritin	153	PT20 400mg	鹽鏇選膚蓋築膚齋衊鏇(蓋簾膚壓鬱網觸廠構壓) = 選襯鑰壓鏇憲範觸獵憲鹹鏇餘獵齋構憲遞膚鑰 (廠選構築壓製夢襯觸觸 )	积极	2015-11-03
				PT20 800mg	鹽鏇選膚蓋築膚齋衊鏇(蓋簾膚壓鬱網觸廠構壓) = 遞醖顧壓鹽鹽壓鹽網襯鹹鏇餘獵齋構憲遞膚鑰 (廠選構築壓製夢襯觸觸 )